The European Union has granted CE mark approval to BG Medicine’s diagnostic blood assay, designed to identify individuals at high-risk for near-term major cardiovascular events including heart attack and stroke.

Using algorithmic analysis, the multivariate index CardioSCORE test combines the results of seven reimbursed protein biomarkers to yield a single numerical score, ranging from 0.0 to 10.0.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Higher values indicate elevated risk for a major cardiovascular event in the subsequent three years, and each 1.0 point increment represents a 30% increase in relative risk, according to the company.

The results obtained from the test will help facilitate clinicians to provide appropriate therapy, enabling preventive intervention.

"The results obtained from the test will help facilitate clinicians to provide appropriate therapy, enabling preventive intervention."

BioImage, the primary clinical validation study for the CardioSCORE, demonstrated that of 6,600 patient who experienced a near-term major cardiovascular event during follow-up, only 26% were identified as being at high risk at baseline by traditional risk factors, whereas 54% were identified as being at high risk upon addition of their CardioSCORE result (p<0.0001).

See Also:

BG Medicine president and CEO Eric Bouvier said the company believes that the test will be pivotal in the primary prevention of major cardiovascular events and treatment of disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We are working aggressively to launch the test in the first half of 2013 in Europe in collaboration with specialty laboratory partners," Bouvier said.

"BG Medicine now has two products covering the continuum of heart disease diagnostics, positioning us strongly to drive the clinical usage of our important diagnostic tests for millions of patients who will benefit from them throughout the world."

BG Medicine said it is continuing its active discussions with the Food and Drug Administration for 510(k) clearance, to make the test available in the US.